16,99 €
16,99 €
inkl. MwSt.
Sofort per Download lieferbar
payback
0 °P sammeln
16,99 €
16,99 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
0 °P sammeln
Als Download kaufen
16,99 €
inkl. MwSt.
Sofort per Download lieferbar
payback
0 °P sammeln
Jetzt verschenken
16,99 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
0 °P sammeln
  • Format: ePub

Leading experts in the cancer field, from doctors to policymakers to academics and more--reflect on the 50 years since Nixon declared the War on Cancer. In 1971, Richard Nixon signed into law a revelatory new program dedicated to cancer research and prevention. This legislation was an amendment to the Public Health Service Act of 1944 and represented the U.S. commitment to what President Nixon described as the "war on cancer," which had become the nation's second leading cause of death by 1970. Fifty years later, the leading experts have come together to reflect on how far this legislation…mehr

  • Geräte: eReader
  • mit Kopierschutz
  • eBook Hilfe
  • Größe: 4.49MB
Produktbeschreibung
Leading experts in the cancer field, from doctors to policymakers to academics and more--reflect on the 50 years since Nixon declared the War on Cancer.
In 1971, Richard Nixon signed into law a revelatory new program dedicated to cancer research and prevention. This legislation was an amendment to the Public Health Service Act of 1944 and represented the U.S. commitment to what President Nixon described as the "war on cancer," which had become the nation's second leading cause of death by 1970. Fifty years later, the leading experts have come together to reflect on how far this legislation has gone, its successes, failures and the road still ahead.
Edited by Abbe Gluck, Professor of Law and Faculty Director of the Solomon Center for Health Law and Policy, and Dr. Charles Fuchs, Director of Yale Cancer Center, these essays span the various implications of cancer on American society; from groundbreaking research, important policies, law, philanthropy and more. With an introduction by Siddartha Mukherjee, other notable contributors include Ezekiel Emanuel, Matthew Nygun, Greg Simon and more.

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CZ, D, DK, EW, E, FIN, F, GR, HR, H, I, LT, L, LR, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Abbe R. Gluck is  is the Alfred M. Rankin Professor of Law, the founding faculty director of the Solomon Center for Health Law and Policy at Yale Law School, professor of internal medicine at Yale School of Medicine and the faculty director of the Yale Medical-Legal Partnership. She is also a Professor in the Institution for Social and Policy Studies at Yale. Gluck is an expert on Congress, federalism, litigation, and health law and is the author of more than 60 articles in law, health and mainstream publications, as well as the author of a leading legislation casebook. After graduation from Yale Law School, Gluck clerked for U.S. Supreme Court Justice Ruth Bader Ginsburg and worked on the senior staffs in the administrations of NYC Mayor Michael Bloomberg and NJ Governor Jon Corzine. Gluck filed influential amicus briefs in all of the major ACA challenges.     Charles S. Fuchs MD, MPH is Senior Vice President and Global Head of Product Development for Oncology and Hematology at Genentech and Roche, former Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital, and Adjunct Professor of Medicine at Yale Cancer Center. Dr. Fuchs has spent his career advancing and enabling great science toward improving the lives of people with cancer. An internationally recognized expert in cancer care, treatment, and prevention, he was previously Professor of Medicine at Harvard Medical School and Chief of the Gastrointestinal Oncology Division and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute. Dr. Fuchs’ research and laboratory include work in molecular epidemiology, translational science, and drug development with over 700 publications and multiple FDA approvals of new cancer therapies.